Fluoguide (FLUO SF)

FluoGuide A/S is a clinical-stage biotechnology company that develops drugs for precision cancer surgery. The company's lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. This technology aims to reduce the risk of local recurrence, minimize surgical complications, and lower healthcare costs. FG001 has been studied in aggressive brain cancer (high-grade glioma), lung cancer, and head and neck cancer. Beyond surgical guidance, FG001 also has potential therapeutic applications as a photosensitizer in photothermal and photodynamic therapies. The company has collaborations with medical technology companies to advance the development and commercialization of its products.